HOME >> BIOLOGY >> NEWS
OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer

te, and reinforces our position as the leader in this emerging area of cancer therapy."

"The pre-clinical and early clinical experience of CA4P makes the compound extremely well-suited for study in Phase II," said the trial's lead investigator, Scot C. Remick, M.D., Associate Professor of Medicine and International Health at University Hospitals of Cleveland and Case Western Reserve University School of Medicine. "Based on our Phase I experience, we are very pleased to continue development of this compound for the treatment of ATC. This clinical trial offers a unique opportunity to investigate a novel anti-tumor treatment, and to potentially establish CA4P as a new therapy."

In addition to the trial announced today, a Phase Ib trial of CA4P is underway at the University of Pennsylvania's Presbyterian Medical Center, where researchers are studying the VTA in combination with a chemotherapy drug called Carboplatin.

CA4P attacks the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels. The compound triggers a change in the shape of endothelial cells lining a tumor's blood vessels. This in turn blocks the flow of blood to the tumor, depriving it of oxygen and nutrients. The compound is a synthetic form of CA4, a natural substance found in the bark of the South African willow tree known as combretum caffrum. CA4 was identified and isolated in 1987 by Professor G. Robert Pettit, director of the Cancer Research Institute at Arizona State University.

"Our Phase II study represents an opportunity to assess the preliminary efficacy of CA4P in a specific indication," said Dai Chaplin, Ph.D., OXiGENE's chief scientific officer. "This is particularly exciting because our Phase I study resulted in a complete pathological response in a patient with the identical disease."


'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
23-Dec-2002


Page: 1 2

Related biology news :

1. OXiGENE launches significant expansion of its R&D program in ophthalmology
2. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
3. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Popular Science announces Third Annual Brilliant 10
7. The American Phytopathological Society announces 2004 awards
8. NSF announces six FIBR awards to tackle some of biologys most challenging questions
9. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
10. JGI announces community sequencing program portfolio
11. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
Breaking Biology Technology:
Cached News: